Effective treatment of infectious diseases requires an understanding of the pharmacokinetics (PK) of drugs used, as well as the pharmacodynamics (PD) of drug action. Evaluation of how PK varies in special populations, or with drug interactions may inform strategies to improve outcomes and reduce treatment failure. The relationship between PK and PD (both for safety and efficacy) is critical to understanding the risk versus benefits of treatment.
Modern treatments for both TB and HIV have delivered good outcomes, yet there is a need for research in the following areas: HIV – improving assessment of adherence (now the major cause of treatment failure), drug penetration into compartments (for durable suppression, or prevention of infection), and characterising drug-drug interactions (DDIs) TB – improving sterilisation of bacilli for ultra-short course therapy, assessing adherence and pulmonary pharmacology.
This PhD studentship will study the pharmacology of HIV/TB therapy, focussing on the following: • Developing new assays for clinical application. This involves new drugs, as well as measuring drugs in extended matrices- such as filter paper, breast milk, cells, tissues, urine/saliva or exhaled breath condensate. • Clinical studies for modelling treatment adherence, DDIs, and drug exposure in pregnancy.